688136.SH
Kexing Biopharm Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 19.59
+3.38%Year over year
Reported trailing growth
- Revenue
- +4.4%
- EBITDA
- —
- EBIT
- +32.9%
- EPS
- +150.2%
- Free cash flow
- —
- Operating cash flow
- -51.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.2%
- EBITDA
- +73.4%
- EBIT
- +166.0%
- Net income
- +394.2%
- EPS
- +393.8%
- Free cash flow
- -81.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026